Drugs / Bacille Calmette-Guerin
Bacille Calmette-Guerin
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02792192 | Jun 2016 → Sep 2020 | urinary bladder cancer | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03888924 | Jun 2019 → Jul 2026 overdue | multiple sclerosis | S. Andrea Hospital | Recruiting | No outcome recorded |
| Phase 43 trials · 1 missed | ||||||
| Phase 4 | NCT02953327 | Feb → Jun 2017 | — | Bandim Health Project | Completed | No outcome recorded |
| Phase 4 | NCT00146302 | Nov 2002 → Mar 2008 | tuberculosis | Bandim Health Project | Completed | Missed primary |
| Phase 4 | NCT00126217 | Jul 2002 → May 2006 | malaria | Bandim Health Project | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01082510 Comparator | Jan 2010 → Dec 2017 | urinary bladder cancer | Urological Oncology Council of Northern Tokyo | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bacille Calmette Guerin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00146302 ↗ |
| Known as | Bacillus Calmette-Guérin | “The beneficial effects of Bacillus Calmette-Guérin (BCG) as an intervention against non-mycobacterial infections have been extensively studied in randomized trials.” PMID 39423450 ↗ Oct 20241“50 μg of the semi-dry mass of BCG bacilli, i.e. from 150,000 to 600,000 of live BCG bacilli (Bacillus Calmette-Guerin), the Brazilian Moreau substrain.” NCT03888924 ↗ |
| Known as | BCG | “50 μg of the semi-dry mass of BCG bacilli, i.e. from 150,000 to 600,000 of live BCG bacilli (Bacillus Calmette-Guerin), the Brazilian Moreau substrain.” NCT03888924 ↗2“BCG vaccine protects non-specifically against other diseases than tuberculosis.” PMID 32201619 ↗ Mar 2020 “Bacille Calmette Guerin (BCG)” NCT00126217 ↗ |
| Modality | Vaccine | “The BCG vaccine given will be the standard dose of 0.1 ml as recommended by WHO in this age group.” NCT00126217 ↗ |
| Route | Other | “BCG will be administered (intravesically) at de-escalated doses.” NCT02792192 ↗ |